相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588
Paul W. Manley et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2013)
Overcoming acquired resistance to kinase inhibition: The cases of EGFR, ALK and BRAF
Simon Giroux
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Inhibitors of JAK2 and JAK3: an update on the patent literature 2010-2012
Brian W. Dymock et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2013)
ALK in Lung Cancer: Past, Present, and Future
Alice T. Shaw et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Synthesis, Structure-Activity Relationships, and in Vivo Efficacy of the Novel Potent and Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) Currently in Phase 1 and Phase 2 Clinical Trials
Thomas H. Marsilje et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study
Takashi Seto et al.
LANCET ONCOLOGY (2013)
Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Anaplastic Lymphoma Kinase Is Required for Neurogenesis in the Developing Central Nervous System of Zebrafish
Sheng Yao et al.
PLOS ONE (2013)
Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non-Small Cell Lung Cancer
Jim Sang et al.
CANCER DISCOVERY (2013)
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
Bengt Hallberg et al.
NATURE REVIEWS CANCER (2013)
Treatment of ALK-Positive Non-Small Cell Lung Cancer
Yung-Jue Bang
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2012)
Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)
Kazutomo Kinoshita et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRα and kit
Xianming Deng et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases
Craig A. Zificsak et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2012)
The battle against ALK resistance: successes and setbacks
Claudia Voena et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Inhibitors of the anaplastic lymphoma kinase
Luca Mologni
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2012)
Strategies to Mitigate the Bioactivation of 2-Anilino-7-Aryl-Pyrrolo[2,1-f][1,2,4]triazines: Identification of Orally Bioavailable, Efficacious ALK Inhibitors
Eugen F. Mesaros et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Design, Synthesis, and Anaplastic Lymphoma Kinase (ALK) Inhibitory Activity for a Novel Series of 2,4,8,22-Tetraazatetracyclo[14.3.1.13,7.19,13]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene Macrocycles
Henry J. Breslin et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Rapid Development of Piperidine Carboxamides as Potent and Selective Anaplastic Lymphoma Kinase Inhibitors
Marian C. Bryan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Discovery of an Orally Efficacious Inhibitor of Anaplastic Lymphoma Kinase
Diane E. Gingrich et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
The Discovery and Optimization of a Novel Class of Potent, Selective, and Orally Bioavailable Anaplastic Lymphoma Kinase (ALK) Inhibitors with Potential Utility for the Treatment of Cancer
Richard T. Lewis et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
CEP-28122, a Highly Potent and Selective Orally Active Inhibitor of Anaplastic Lymphoma Kinase with Antitumor Activity in Experimental Models of Human Cancers
Mangeng Cheng et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Treating ALK-positive lung cancer-early successes and future challenges
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Development and Scale-Up of an Optimized Route to the ALK Inhibitor CEP-28122
Shawn P. Allwein et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2012)
Design of 7-amino-6-chloro-3H-imidazo[4,5-b]pyridine scaffold from 5-chloro-2,4-diaminopyrimidine pharmacophore: identification of potent inhibitors of anaplastic lymphoma kinase
Keith S. Learn et al.
MEDCHEMCOMM (2012)
Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models
Eugen F. Mesaros et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors
Kazutomo Kinoshita et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors
Craig A. Zificsak et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: Modification of target structure to minimize reactive metabolite formation
Linda R. Weinberg et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Hiroshi Sakamoto et al.
CANCER CELL (2011)
Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
Christine M. Lovly et al.
CANCER RESEARCH (2011)
2,7-Disubstituted-Pyrrolotriazine Kinase Inhibitors with an Unusually High Degree of Reactive Metabolite Formation
Kevin J. Wells-Knecht et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2011)
Design, Synthesis, and Biological Activity of Urea Derivatives as Anaplastic Lymphoma Kinase Inhibitors
Gustav Boije af Gennas et al.
CHEMMEDCHEM (2011)
2,7-Disubstituted-pyrrolo[2,1-f][1,2,4]triazines: New Variant of an Old Template and Application to the Discovery of Anaplastic Lymphoma Kinase (ALK) Inhibitors with in Vivo Antitumor Activity
Gregory R. Ott et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors
Kazutomo Kinoshita et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Targeting Oncogenic ALK: A Promising Strategy for Cancer Treatment
Enrique Grande et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools
Olaf Merkel et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Managing the challenge of chemically reactive metabolites in drug development
B. Kevin Park et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Discovery and Process Synthesis of Novel 2,7-Pyrrolo[2,1-f][1,2,4]triazines
Tho Thieu et al.
ORGANIC LETTERS (2011)
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Ryohei Katayama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Crystal Structures of Anaplastic Lymphoma Kinase in Complex with ATP Competitive Inhibitors
Roberto T. Bossi et al.
BIOCHEMISTRY (2010)
Inhibitors of anaplastic lymphoma kinase: a patent review
Karen L. Milkiewicz et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2010)
Discovery of a Potent Inhibitor of Anaplastic Lymphoma Kinase with in Vivo Antitumor Activity
Gregory R. Ott et al.
ACS MEDICINAL CHEMISTRY LETTERS (2010)
Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)
Christopher J. Burns et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2009)
Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy
Thomas R. Webb et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery
Arup K. Ghose et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
The anaplastic lymphoma kinase in the pathogenesis of cancer
Roberto Chiarle et al.
NATURE REVIEWS CANCER (2008)
Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
James G. Christensen et al.
MOLECULAR CANCER THERAPEUTICS (2007)
An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Helen Y. Zou et al.
CANCER RESEARCH (2007)
Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells
WH Wan et al.
BLOOD (2006)
Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas
R Piva et al.
BLOOD (2006)
Anaplastic lymphoma kinase proteins in growth control and cancer
K Pulford et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2004)
Cell signaling by receptor tyrosine kinases
J Schlessinger
CELL (2000)
分享论文
